{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:06:08Z","timestamp":1791302768386,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.autrev.2011.04.025","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T04:22:55Z","timestamp":1305001375000},"page":"693-701","source":"Crossref","is-referenced-by-count":38,"title":["Systemic sclerosis refractory disease: From the skin to the heart"],"prefix":"10.1016","volume":"10","author":[{"given":"Isabel","family":"Almeida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2011.04.025_bb0005","series-title":"Trait\u00e9 des maladies et syndromes syst\u00e9miques","first-page":"410","article-title":"Scl\u00e9rodermie systemique","author":"Mouthon","year":"2009"},{"key":"10.1016\/j.autrev.2011.04.025_bb0010","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2011.04.025_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2362.2006.01688.x","article-title":"Survival in patients with pulmonary arterial hypertension treated with first-line bosenta","volume":"36","author":"McLaughlin","year":"2006","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.autrev.2011.04.025_bb0020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/hrt.2005.069484","article-title":"Systemic sclerosis associated pulmonary hypertension: improved survival in the current era","volume":"92","author":"Williams","year":"2006","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.autrev.2011.04.025_bb0025","first-page":"1471","article-title":"When is scleroderma really scleroderma?","volume":"28","author":"Wigley","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bmt.1701987","article-title":"Autologous haematopoietic stem cell transplants for autoimmune disease \u2014 feasibility and transplant-related mortality","volume":"24","author":"Tyndall","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.autrev.2011.04.025_bb0035","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.autrev.2011.04.025_bb0040","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group EUSTAR","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2011.04.025_bb0045","first-page":"S42","article-title":"Assessment of disease severity and prognosis","volume":"21","author":"Medsger","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semarthrit.2007.01.005","article-title":"Update on indices of disease activity in systemic sclerosis","volume":"37","author":"Hudson","year":"2007","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.rdc.2007.11.005","article-title":"Current approaches to the management of early active diffuse scleroderma skin disease","volume":"34","author":"Nihtyanova","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2011.04.025_bb0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/BOR.0b013e328335a7d2","article-title":"Musculoskeletal rehabilitation in the person with scleroderma","volume":"22","author":"Poole","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0065","first-page":"1281","article-title":"Inter- and intraobserver variability of total skin thickness core (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0070","first-page":"84","article-title":"The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis","volume":"25","author":"Furst","year":"1998","journal-title":"J Rheumatol"},{"issue":"Suppl. 29","key":"10.1016\/j.autrev.2011.04.025_bb0075","first-page":"S5","article-title":"Assessment of skin, joint, tendon and muscle involvement","volume":"21","author":"Akesson","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0080","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/40.1.84","article-title":"Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma","volume":"40","author":"Stratton","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.autrev.2011.04.025_bb0085","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","article-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","volume":"70","author":"Le","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2011.04.025_bb0090","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/rheumatology\/kep295","article-title":"A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis","volume":"48","author":"Derk","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2011.04.025_bb0095","first-page":"613","article-title":"Twelve-month azathioprine as maintainance therapy in early diffuse systemic sclerosis patients treated for 1-year with low-dose cyclophosphamide pulse therapy","volume":"25","author":"Paone","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.04.025_bb0105","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2011.04.025_bb0110","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/ken104","article-title":"Imatinib for the treatment of refractory, diffuse systemic sclerosis","volume":"47","author":"Sfikakis","year":"2008","journal-title":"Rheumatology"},{"issue":"69","key":"10.1016\/j.autrev.2011.04.025_bb0115","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/BOR.0b013e32833f1105","article-title":"Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis","volume":"22","author":"Gordon","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2011.04.025_bb0120","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","article-title":"Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial","volume":"70","author":"Spiera","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2011.04.025_bb0125","first-page":"664","article-title":"Clinical effects of tocilizumab, a humanized anti-interleukin-6 receptor antibody on patients with autoimmune and inflammatory diseases","volume":"69","author":"Ogata","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.autrev.2011.04.025_bb0130","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2011.04.025_bb0135","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/BOR.0b013e328337c3d6","article-title":"Innovative therapies for systemic sclerosis","volume":"22","author":"Ong","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2011.04.025_bb0140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1365-2133.2008.09004.x","article-title":"Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors","volume":"160","author":"Sunderk\u00f6tter","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0145","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.2007.072686","article-title":"Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis","volume":"67","author":"Nihtyanova","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.autrev.2011.04.025_bb0150","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.025_bb0155","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1093\/rheumatology\/kem190","article-title":"Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity","volume":"46","author":"Caramaschi","year":"2007","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.autrev.2011.04.025_bb0160","first-page":"199","article-title":"Correlazione di uno score quantitative capillaroscopico con lo sviluppo di ulcere ischemiche digitali nei pazienti com sclerosi sist\u00e9mica","volume":"60","author":"Sebastini","year":"2008","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2011.04.025_bb0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.rdc.2007.11.006","article-title":"Diagnosis and management of scleroderma peripheral vascular disease","volume":"24","author":"Herrick","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"S1","key":"10.1016\/j.autrev.2011.04.025_bb0170","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1093\/ajcn\/71.1.352s","article-title":"Evening primrose oil and borage oil in rheumatologic conditions","volume":"71","author":"Belch","year":"2000","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0175","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.autrev.2008.07.002","article-title":"Treatment of Raynaud's phenomenon","volume":"8","author":"Garcia-Carrasco","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"19","key":"10.1016\/j.autrev.2011.04.025_bb0180","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy","volume":"112","author":"Fries","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.autrev.2011.04.025_bb0185","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.025_bb0190","first-page":"642","article-title":"Surgery of the hand in patients with systemic sclerosis: outcomes and considerations","volume":"32","author":"Bogoch","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0195","first-page":"269","article-title":"Adventitial stripping: a digit saving procedure in refractory Raynaud's phenomena","volume":"25","author":"Yee","year":"1998","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.autrev.2011.04.025_bb0200","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/art.1780400620","article-title":"The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 58","key":"10.1016\/j.autrev.2011.04.025_bb0205","first-page":"S28","article-title":"Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis","volume":"28","author":"Torok","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0210","doi-asserted-by":"crossref","DOI":"10.1007\/s00296-010-1697-6","article-title":"Corticosteroids and the risk of scleroderma renal crisis: a systematic review","author":"Trang","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2011.04.025_bb0215","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/art.1780370902","article-title":"Gastrointestinal disorders in scleroderma","volume":"37","author":"Sjogren","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.025_bb0220","first-page":"S15","article-title":"Assessment of gastrointestinal involvement","volume":"21","author":"Clements","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2011.04.025_bb0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RHU.0b013e3180645d2a","article-title":"Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients","volume":"13","author":"Nikou","year":"2007","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0230","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","article-title":"Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma","volume":"325","author":"Soudah","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.autrev.2011.04.025_bb0235","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.disamonth.2010.12.007","article-title":"Gastroparesis: approach, diagnostic evaluation, and management","volume":"57","author":"Tang","year":"2011","journal-title":"Dis Mon"},{"key":"10.1016\/j.autrev.2011.04.025_bb0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","article-title":"Scleroderma renal crisis","volume":"29","author":"Steen","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2011.04.025_bb0245","series-title":"The kidney in systemic autoimmune diseases","first-page":"363","article-title":"The kidney in systemic sclerosis","author":"Steen","year":"2008"},{"issue":"11","key":"10.1016\/j.autrev.2011.04.025_bb0250","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1002\/art.10589","article-title":"Predictors and outcomes of scleroderma renal crisis","volume":"46","author":"De Marco","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.025_bb0255","doi-asserted-by":"crossref","first-page":"iii32","DOI":"10.1093\/rheumatology\/ken483","article-title":"Renal complications and scleroderma renal crisis","volume":"48","author":"Denton","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2011.04.025_bb0260","series-title":"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults, UpToDate 19.1","author":"Varga","year":"2011"},{"issue":"5","key":"10.1016\/j.autrev.2011.04.025_bb0265","doi-asserted-by":"crossref","first-page":"352","DOI":"10.7326\/0003-4819-113-5-352","article-title":"Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors","volume":"113","author":"Steen","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2011.04.025_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2010.11.001","article-title":"Anti-neutrophil antibody associated vasculitis in systemic sclerosis","author":"Arad","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.04.025_bb0275","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00296-005-0011-5","article-title":"Scleroderma associated with ANCA-associated vasculitis","volume":"26","author":"Rho","year":"2006","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0280","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11926-009-0078-1","article-title":"Diagnosis and management of pulmonary hypertension in systemic sclerosis","volume":"12","author":"Sweiss","year":"2010","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.autrev.2011.04.025_bb0285","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0290","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/rheumatology\/keh474","article-title":"Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?","volume":"44","author":"Black","year":"2005","journal-title":"Rheumatology"},{"issue":"Suppl. 29","key":"10.1016\/j.autrev.2011.04.025_bb0295","first-page":"S19","article-title":"Assessment of lung involvement","volume":"21","author":"Matucci-Cerinic","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0300","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"30","author":"Galie","year":"2009","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.autrev.2011.04.025_bb0305","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1183\/09031936.00058409","article-title":"Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension","volume":"34","author":"Lavelle","year":"2009","journal-title":"ERJ"},{"issue":"6","key":"10.1016\/j.autrev.2011.04.025_bb0310","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/BOR.0b013e3283307dc8","article-title":"Therapy for pulmonary arterial hypertension associated with systemic sclerosis","volume":"21","author":"Mathai","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0315","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/ken369","article-title":"A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide","volume":"48","author":"Sabnani","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2011.04.025_bb0320","doi-asserted-by":"crossref","first-page":"iii49","DOI":"10.1093\/rheumatology\/kep106","article-title":"Future targets in the management of systemic sclerosis","volume":"48","author":"Tyndall","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2011.04.025_bb0325","series-title":"Pulmonary involvement in systemic autoimmune diseases","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1571-5078(04)02003-3","article-title":"Pulmonary arterial hypertension in connective tissue disease","author":"Denton","year":"2004"},{"key":"10.1016\/j.autrev.2011.04.025_bb0330","series-title":"Pulmonary involvement in systemic autoimmune diseases","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1571-5078(04)02010-0","article-title":"Interstitial disease in systemic sclerosis","author":"Goh","year":"2004"},{"key":"10.1016\/j.autrev.2011.04.025_bb0335","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874306400802010039","article-title":"Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study","volume":"2","author":"Sime\u00f3n-Aznar","year":"2008","journal-title":"Open Respir Med J"},{"issue":"11","key":"10.1016\/j.autrev.2011.04.025_bb0340","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2011.04.025_bb0345","series-title":"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma), UpToDate 19.1","author":"Vargas","year":"2011"},{"issue":"25","key":"10.1016\/j.autrev.2011.04.025_bb0350","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2011.04.025_bb0355","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2011.04.025_bb0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1378\/chest.06-2861","article-title":"Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease","volume":"133","author":"Gerbino","year":"2008","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0365","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.rmed.2007.07.021","article-title":"Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease","volume":"102","author":"Zamora","year":"2008","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.autrev.2011.04.025_bb0370","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"Liossis","year":"2006","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.autrev.2011.04.025_bb0375","first-page":"287","article-title":"A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis","volume":"25","author":"Vanthuyne","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2011.04.025_bb0380","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis \u2014 a retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.autrev.2011.04.025_bb0385","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10067-004-0906-7","article-title":"Experience with azathioprine in systemic sclerosis associated with interstitial lung disease","volume":"23","author":"Dheda","year":"2004","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2011.04.025_bb0390","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis","volume":"25","author":"Nadashkevich","year":"2006","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2011.04.025_bb0395","doi-asserted-by":"crossref","first-page":"181-viii","DOI":"10.1016\/j.rdc.2007.12.002","article-title":"The heart in scleroderma","volume":"34","author":"Champion","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl. 29","key":"10.1016\/j.autrev.2011.04.025_bb0400","first-page":"S24","article-title":"Assessment of heart involvement","volume":"21","author":"Ferri","year":"2003","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl. 62","key":"10.1016\/j.autrev.2011.04.025_bb0405","first-page":"S48","article-title":"Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin","volume":"28","author":"Allanore","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.04.025_bb0410","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ejim.2008.10.011","article-title":"Systolic and diastolic function in patients with systemic sclerosis","volume":"20","author":"Poanta","year":"2009","journal-title":"Eur J Intern Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211000930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211000930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T17:19:52Z","timestamp":1560187192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211000930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":82,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1568997211000930"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.04.025","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}